HDAC9 nuclear/cytoplasmic shuttling in pulmonary vascular endothelial barrier regulation
HDAC9核/细胞质穿梭在肺血管内皮屏障调节中的作用
基本信息
- 批准号:10446078
- 负责人:
- 金额:$ 38.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-02 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:Acute Lung InjuryAcute Respiratory Distress SyndromeAdherens JunctionAffectAgonistAntibioticsBacteriaBacterial InfectionsBacterial ToxinsBlood VesselsCell NucleusClinicalComplexCytoplasmCytoplasmic ProteinCytoskeletal ProteinsCytosolDataDeacetylationDevelopmentEndothelial CellsEndotheliumEscherichia coliFunctional disorderGAB1 geneGoalsHDAC9 geneHGF geneHistone DeacetylaseHumanIn VitroInflammationInflammatory ResponseIntensive CareInvestigationKnockout MiceLeadLinkLipopolysaccharidesLungMediatingModelingMolecularMusNuclearNuclear ExportNuclear ImportPathologicPatientsPermeabilityPharmacologyPhosphorylationPhosphotransferasesPropertyProtein DephosphorylationProtein phosphataseProteinsPulmonary CirculationPulmonary EdemaRegulationRespiratory distressRoleSepsisSignal TransductionSignaling ProteinSourceSyndromeTestingTranscription RepressorTransgenic MiceVascular Endothelial CellVascular EndotheliumVascular Permeabilitiesanalogbeta cateningenetic corepressorimprovedin vivolung microvascular endothelial cellsmortalitynovelnovel therapeutic interventionoverexpressionplakoglobinprotective effectprotein activationpulmonary functionreceptor
项目摘要
PROJECT SUMMARY
Acute lung injury (ALI) is characterized by lung vascular endothelial (EC) barrier compromise resulting in
pulmonary edema. Gram negative (G-) bacteria are the source of bacterial toxins such as lipopolysaccharides
(LPS), which are potent triggers of ALI. Despite the use of potent antibiotics and aggressive intensive care
support, the mortality of LPS-induced ALI remains high, primarily because the complex molecular mechanisms
involved in EC barrier regulation are ill-defined. The Scientific Premise of this Project derives from our novel
preliminary data indicating that the class IIa histone deacetylase, HDAC9, is upregulated in the lungs of patients
with sepsis in concert with the inflammatory responses. Accordingly, the overexpression of HDAC9 in transgenic
mice increases basal lung vascular permeability and exacerbates vascular barrier compromise induced by LPS.
Conversely, deletion of HDAC9 gene improves lung function in LPS-induced murine ALI model. These data
suggest pro-edemagenic role of HDAC9 expression in ALI. HDAC9 is nuclear-cytoplasmic protein and its cellular
localization is regulated by phosphorylation. Phosphorylation leads to HDAC9 nuclear export thus inhibiting its
activity in the nucleus and promoting interactions with extra-nuclear targets. We demonstrated that LPS
increases HDAC9 phosphorylation accompanied by its nuclear export in EC. In contrary, de-phosphorylation of
HDAC9 leads to nuclear import thus inhibiting its association with cytoplasmic proteins. We showed that HDAC9
interacts with protein phosphatase 2A (PP2A), which has a barrier-protective role in EC. Further, our novel data
indicated that PP2A is activated by Gi-mediated EC barrier-protective agonists, HGF and the stable ATP analog,
ATPγS, suggesting the link between Gi-mediated signaling and PP2A in EC barrier enhancement. While the
mechanisms of Gi-mediated PP2A activation have not been described, our data suggest that they may include
the activation of GAB1/Shp2-mediated signaling. Further, both HDAC9 and PP2A interact with AJ protein
plakoglobin suggesting functional complex. However, whether the HDAC9-dependent EC barrier regulation
involved HDAC9/PP2A/plakoglobin interaction and EC barrier-protective effect of PP2A is mediated through
decreased HDAC9 phosphorylation is not yet established. Therefore, a primary goal of this Proposal will be to
define a novel role for HDAC9/PP2A crosstalk in AJ-mediated EC barrier regulation. We hypothesize that the
phosphorylation status of HDAC9 and its interaction with PP2A alter intracellular signaling to regulate the EC
barrier via effect on AJ assembly. The SAs are: 1: To evaluate the role of HDAC9 phosphorylation/nuclear export
in the LPS-induced adherens junctions-mediated endothelial barrier compromise in vitro and in vivo. 2: To
determine the importance of PP2A-mediated HDAC9 dephosphorylation/nuclear import in the assembly of AJs
and endothelial barrier strengthening in vitro and in vivo.
项目概要
急性肺损伤(ALI)的特点是肺血管内皮(EC)屏障受损,导致
肺水肿。革兰氏阴性 (G-) 细菌是脂多糖等细菌毒素的来源
(LPS),这是 ALI 的有效触发因素。尽管使用强效抗生素和积极的重症监护
支持,LPS 诱导的 ALI 死亡率仍然很高,主要是因为复杂的分子机制
EC 屏障调节的参与尚不明确。该项目的科学前提源自我们的小说
初步数据表明 IIa 类组蛋白脱乙酰酶 HDAC9 在患者肺部表达上调
脓毒症与炎症反应相一致。因此,HDAC9在转基因中的过度表达
小鼠的基础肺血管通透性增加,并加剧 LPS 引起的血管屏障损害。
相反,HDAC9 基因的缺失可改善 LPS 诱导的小鼠 ALI 模型中的肺功能。这些数据
表明 HDAC9 表达在 ALI 中具有促水肿作用。 HDAC9 是核质蛋白及其细胞
定位受磷酸化调节。磷酸化导致 HDAC9 核输出,从而抑制其
核内的活动并促进与核外目标的相互作用。我们证明了 LPS
增加 HDAC9 磷酸化并伴随其在 EC 中的核输出。相反,去磷酸化
HDAC9 导致核输入,从而抑制其与细胞质蛋白的结合。我们证明了 HDAC9
与蛋白磷酸酶 2A (PP2A) 相互作用,后者在 EC 中具有屏障保护作用。此外,我们的新颖数据
表明 PP2A 被 Gi 介导的 EC 屏障保护激动剂、HGF 和稳定的 ATP 类似物激活,
ATPγS,表明 Gi 介导的信号传导与 PP2A 在 EC 屏障增强中的联系。虽然
Gi 介导的 PP2A 激活机制尚未描述,我们的数据表明它们可能包括
GAB1/Shp2 介导的信号传导的激活。此外,HDAC9 和 PP2A 均与 AJ 蛋白相互作用
斑珠蛋白提示功能复合物。然而,HDAC9 依赖性 EC 屏障调节是否
涉及 HDAC9/PP2A/plakoglobin 相互作用,PP2A 的 EC 屏障保护作用是通过介导的
HDAC9 磷酸化降低的情况尚未确定。因此,本提案的主要目标是
定义了 HDAC9/PP2A 串扰在 AJ 介导的 EC 屏障调节中的新作用。我们假设
HDAC9 的磷酸化状态及其与 PP2A 的相互作用改变细胞内信号传导以调节 EC
屏障通孔对 AJ 装配的影响。 SA 是: 1:评估 HDAC9 磷酸化/核输出的作用
在体外和体内 LPS 诱导的粘附连接介导的内皮屏障受损中。 2:至
确定 PP2A 介导的 HDAC9 去磷酸化/核导入在 AJ 组装中的重要性
以及体外和体内内皮屏障的强化。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALEXANDER D VERIN其他文献
ALEXANDER D VERIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALEXANDER D VERIN', 18)}}的其他基金
HDAC9 nuclear/cytoplasmic shuttling in pulmonary vascular endothelial barrier regulation
HDAC9核/细胞质穿梭在肺血管内皮屏障调节中的作用
- 批准号:
10597538 - 财政年份:2022
- 资助金额:
$ 38.5万 - 项目类别:
Rac1 Stimulation in Adenosine-Induced Barrier Protection
Rac1 刺激腺苷诱导的屏障保护
- 批准号:
8198064 - 财政年份:2011
- 资助金额:
$ 38.5万 - 项目类别:
Mini-plasmin: Pre-Clinical Evaluation of a Novel Thrombolytic Strategy for Stroke
微型纤溶酶:中风新型溶栓策略的临床前评估
- 批准号:
8215615 - 财政年份:2011
- 资助金额:
$ 38.5万 - 项目类别:
Endothelial Barrier Protection and Repair in Acute Lung Injury
急性肺损伤中的内皮屏障保护和修复
- 批准号:
8690947 - 财政年份:2011
- 资助金额:
$ 38.5万 - 项目类别:
Microtubule involvement in lung endothelial pathobiology
微管参与肺内皮病理学
- 批准号:
7347546 - 财政年份:2007
- 资助金额:
$ 38.5万 - 项目类别:
ALK/SMAD Signaling in TGF beta-induced EC Permeability
TGFβ 诱导的 EC 通透性中的 ALK/SMAD 信号转导
- 批准号:
7446642 - 财政年份:2005
- 资助金额:
$ 38.5万 - 项目类别:
相似海外基金
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 38.5万 - 项目类别:
Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
- 批准号:
10722669 - 财政年份:2023
- 资助金额:
$ 38.5万 - 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
- 批准号:
491387 - 财政年份:2023
- 资助金额:
$ 38.5万 - 项目类别:
Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
- 批准号:
10678788 - 财政年份:2023
- 资助金额:
$ 38.5万 - 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
- 批准号:
10646578 - 财政年份:2023
- 资助金额:
$ 38.5万 - 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
- 批准号:
23K08447 - 财政年份:2023
- 资助金额:
$ 38.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
- 批准号:
10601865 - 财政年份:2023
- 资助金额:
$ 38.5万 - 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
- 批准号:
23K08360 - 财政年份:2023
- 资助金额:
$ 38.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
- 批准号:
10722194 - 财政年份:2023
- 资助金额:
$ 38.5万 - 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
- 批准号:
10594793 - 财政年份:2023
- 资助金额:
$ 38.5万 - 项目类别:














{{item.name}}会员




